Hold CL at $92.55: Tiered entry at $89-$91 with stop $85.50, trim on confirmed close below $89.50 on volume >4M
HOLD maintained at $92.55. The aggressive analyst wins the long-term structural case (0.327 beta, 63-year dividend streak, 22.5x normalized forward P/E, $1.05B net debt reduction YoY, 2.5x FCF coverage of dividend), while the conservative analyst wins the near-term timing case (three failed retests at $93.49, fresh MACD bearish cross Aug 17, operating income declined YoY despite gross margin expansion, 2.33% yield trails 4.5% money market funds). The tiered add framework at $89-$91 with explicit RSI/MACD confirmation is the most executable synthesis, converting passive Hold into defined-actionable stance. Trim trigger at confirmed close <$89.50 on volume >4M; stop at $85.50 (below 200 SMA at $86.34).
| Position | Action |
|---|---|
| Normal defensive staple allocation | 2-4% weight |
Colgate-Palmolive is a misunderstood compounding machine, not an overvalued staples stock—the bear case misreads depressed trailing earnings caused by a one-time impairment as the true earnings power of a business delivering 4.9% revenue growth, 140 bps gross margin expansion, and a 63-year dividend growth streak at just 22.5x forward earnings.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | $91.53 | bullish |
| 50 SMA | $91.58 | bullish |
| 200 SMA | $86.34 | bullish |
| RSI | 53.33 | neutral |
| MACD | −0.064 | bearish |
| MACD Signal | +0.078 | bearish |
| Bollinger Upper Band | $94.32 | neutral |
| Bollinger Middle Band | $91.98 | neutral |
| Bollinger Lower Band | $89.64 | bullish |
| ATR | $2.08 | neutral |
Support: 89.64 · 86.34 | Resistance: 93.49 · 94.32 · 91.98
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
The stock is NOT below its 50-day SMA—the bear's technical breakdown argument has already resolved itself; the long-term trend remains intact with the 200 SMA rising +$4 over three months
↩ rebuts: “Bear technical breakdown thesis”
EV: +$94-$98 (vs current $92.55) · concedes: The tape is choppy with MACD crossover, flattening 10 EMA, and failed retests at $93.50; Momentum has paused in the near term; The 50-day SMA break did occur technically; COKE has outperformed on relative momentum recently
CL at 93% of its 52-week high is a trap, not an opportunity — the stock offers no margin of safety at 22.5x forward P/E (fairly valued vs. sector), negative near-term momentum signals (fresh MACD bearish cross, flattening 10 EMA at $91.53), and a 2.33% yield that is roughly half what money market funds offer with zero equity risk, making the risk/reward asymmetrically unfavorable for new buyers.
· concedes: The moat is real (40%+ global toothpaste share, Hill's Science Diet brand equity); 63-year dividend growth streak is genuine, though fully embedded in the current multiple; Capital allocation (buybacks/dividends) is disciplined on a near-term basis (3x FCF coverage, 1.3x Net Debt/EBITDA); Q2 gross margin expansion of +140 bps is real, though lagging cost pressures from oil shock likely flow through Q3/Q4 2026; The bull's technical and fundamental descriptions of CL are accurate — the disagreement is whether that characterization warrants buying at current levels vs. waiting for pullback
→ vs conservative: Being near a 52-week high at $92.55 in a confirmed uptrend is not a reason to hesitate—the rising 200 SMA at $86.34 and May golden cross confirm the trend; waiting is circular logic
→ vs conservative: 2.33% yield is uncompetitive versus 4.5% money markets, but CL is bought for total return, not current income, and in a no-cut environment the relative attractiveness of dividend growers improves
→ vs conservative: Current geopolitical crisis creating oil supply shock is the ideal backdrop for defensive staples, not a reason to wait for a 'better entry'
→ vs neutral: Waiting for MACD re-cross, lower-high sequence break, or clean entry below $89.50 causes whipsaw risk while stock grinds higher; Bollinger lower band at $89.64 has been successfully defended every time this summer
→ vs neutral: Zacks 'rich valuation' framing ignores that 36x trailing P/E is distorted by non-recurring Q4 2025 goodwill impairment; 22.5x forward P/E on $4.11 normalized EPS is reasonable for 60% gross margins and 4.7% FCF yield
→ vs neutral: Waiting for $89.50 risks missing the move if CL breaks $93.50 on volume and the trader is forced to chase at $95
Colgate-Palmolive exhibits a "stacked bullish alignment" with the 10 EMA ($91.53) and 50 SMA ($91.58) tightly converged above the 200 SMA ($86.34), reflecting a post-golden-cross regime since May 2026. The 10 EMA has flattened (from $92.00 on 07-29 to $91.53 on 08-24), marking the first caution flag for short-term momentum. RSI has oscillated in a 38–66 band over 60 trading days without reaching overbought (70) or oversold (30) extremes, confirming a classic defensive consumer staples range-bound regime. The MACD bearish crossover occurred approximately 08-17-2026, with both lines hovering near zero and the MACD having decayed ~94% from its 07-13 peak of 1.080. Bollinger Bands show band width of $4.68 (~5.1% of price), with price successfully defending the lower band on 08-03 ($89.88 close vs. $89.27 LB) and subsequently bouncing +5%. The critical short-term constraint is a sequence of lower highs failing to retake the 07-29 swing high of $93.49 across five subsequent attempts. Bullish bias remains favored while price holds above $89.50, though aggressive buying is cautioned without MACD re-cross confirmation.
Market Cap
$73.78B
Current Price
$92.55
52-Week High
$99.33
52-Week Low
$74.55
P/E (TTM)
36.4x
Forward P/E
22.5x
PEG Ratio
1.75
P/B
312.7x
Dividend Yield
2.33%
Beta
0.327
EPS (TTM)
$2.54
Forward EPS
$4.11
Revenue Q2 2026
$5.361B
Gross Margin Q2 2026
61.5%
Operating Income Q2 2026
$1.016B
Net Income Q2 2026
$693M
Diluted EPS Q2 2026
$0.86
Revenue Q1 2026
$5.324B
Gross Margin Q1 2026
60.6%
Operating Income Q1 2026
$0.964B
Net Income Q1 2026
$646M
Diluted EPS Q1 2026
$0.80
Revenue Q4 2025
$5.230B
Gross Margin Q4 2025
60.2%
Operating Income Q4 2025
$0.092B
Net Income Q4 2025
($37M)
Diluted EPS Q4 2025
($0.05)
Revenue Q3 2025
$5.131B
Gross Margin Q3 2025
59.4%
Operating Income Q3 2025
$1.059B
Net Income Q3 2025
$735M
Diluted EPS Q3 2025
$0.91
Revenue Q2 2025
$5.110B
Gross Margin Q2 2025
60.1%
Operating Income Q2 2025
$1.080B
Net Income Q2 2025
$743M
Diluted EPS Q2 2025
$0.91
Q4 2025 One-Time Charge
$866M
Cash & Equivalents Q2 2026
$1.370B
Total Current Assets Q2 2026
$6.308B
Total Assets Q2 2026
$16.790B
Total Debt Q2 2026
$7.857B
Net Debt Q2 2026
$6.487B
Stockholders' Equity Q2 2026
$0.236B
Treasury Stock Q2 2026
$28.931B
Current Ratio Q2 2026
1.026
Goodwill Q2 2025
$3.70B
Goodwill Q2 2026
$3.10B
Net Debt / EBITDA
~1.3x
Operating Cash Flow Q2 2026
$995M
Capital Expenditure Q2 2026
($128M)
Free Cash Flow Q2 2026
$867M
Dividends Paid Q2 2026
($462M)
Share Repurchases Q2 2026
($291M)
Total Capital Returned Q2 2026
($753M)
TTM Free Cash Flow
$3.46B
Gross Margin
60.4%
Operating Margin
21.0%
Net Profit Margin
9.7%
Return on Equity (ROE)
267.4%
Return on Assets (ROA)
15.8%
Free Cash Flow Yield
~4.7%
Implied Fair Value Low
$90/share
Implied Fair Value High
$98/share
50-DMA
$91.77
200-DMA
$87.10
% of 52-Week High
93%
Annual Dividend
$1.85B
Dividend Coverage
~3x FCF
Buyback Rate
~$1.2B/yr
Strengths
Concerns
HOLD — High-quality defensive franchise with strong brand equity (Colgate ~40%+ global toothpaste share), disciplined capital allocation, and improving balance sheet quality. Trailing earnings are temporarily distorted by Q4'25 $866M goodwill impairment charge, but forward earnings suggest meaningful ~62% recovery to $4.11 EPS. Valuation is fair, not cheap, with Forward P/E of 22.5x and implied fair value of $90–$98/share at current price of $92.55. The combination of defensive characteristics (Beta 0.327), reliable ~2.33% dividend yield covered 3x by FCF, and visible earnings normalization supports a long-term HOLD, with tactical buying opportunities on pullbacks to the 50-DMA ($91.77) or 200-DMA ($87.10) zones.
Macro: U.S.–Iran conflict is active and escalating with the Strait of Hormuz effectively closed; Citi estimates ~3 mb/d in global observed inventory draws (~519 million barrels) between Feb–Aug 2026 — a sustained oil-supply shock feeding into packaging, surfactants, and freight costs. Polymarket prices 87% probability of no Fed rate cuts in 2026 (up ~1.4pp week-over-week) and only 8% probability of U.S. recession — a soft-landing consensus that supports defensive staples valuations. Gold at $4,640.80/oz (+0.36%) and silver +18% MoM confirm risk-off and inflation-hedge demand, broadly positive for defensive dividend payers on a relative basis. Walmart absorbed a ~$100B market-cap wipeout before rebounding, signaling value-seeking consumer pressure that disproportionately impacts premium-priced portfolios like CL's U.S. business.